Canada offers a premier “Venture” exchange ecosystem specifically designed for growth-stage science. This unique environment allows Life Science companies to access deep public markets significantly earlier in their lifecycle than traditional routes in the US or Korea.
The Canadian markets, specifically the TSX-V and CSE, are home to specialized venture capital pools and sophisticated investors who are accustomed to development-stage issuers. Unlike restricted domestic markets, there is a high acceptance for Pre-IND and pre-revenue Life Science companies, providing the necessary capital supply to fund critical innovation.
Listing in Toronto serves as a strategic pivot point for valuation expansion, offering a gateway to broader North American and European capital markets. By going public on world-class senior exchanges, Korean firms can escape local valuation caps, achieve global visibility, and tap into deep institutional liquidity to fund large-scale North American clinical trials.
Canada provides a unique "Venture" exchange ecosystem that allows Life Science companies to access public markets earlier than in the US or Korea.
Requirement
TSX-V (CPC IPO)
CSE (Standard IPO)
Min Capital
$200k CAD
No Min (12mo WC)
Listing Speed
6-12 Months
4-6 Months
Regulatory
Merit-based
Disclosure-based
We enable earlier access to public equity than traditional domestic routes. Through the Canadian venture ecosystem, Life Science firms can secure funding at pre-revenue or pre-IND stages, preventing delays in critical R&D.
Canadian markets, particularly the TSX-V and CSE, offer a strong base of biopharma investors experienced with early-stage companies. They recognize long-term scientific value and are more open to early-stage financing, creating a supportive environment for Korean SMEs.
Listing on Canadian exchanges provides access to North American and European capital markets. This helps overcome local valuation limits, enhances visibility, and attracts institutional liquidity alongside global peers.
We leverage established routes such as the CPC program and RTOs to streamline the listing process. These widely used pathways provide a predictable and efficient path to market, supported by our cross-border expertise.
This text briefly introduces your service to your visitors.
Use this section to describe the service you offer. You could share your company’s story and details about why you are in business. The goal is to create a connection with the client. Ipsum dolor sit amet consectetur adipiscing. Magna sit amet purus gravida quis. Praesent tristique magna sit amet purus. Turpis nunc eget lorem dolor sed. Dui id ornare arcu odio ut.
We provide comprehensive support for the critical financial transition required to list internationally. Our team manages the conversion of domestic financial statements to Venture IFRS standards and coordinates with international auditors to ensure full regulatory compliance. This foundational service ensures your company is technically prepared for the deep reviews of the TSX or the disclosure requirements of the CSE.
Beyond just financing, we assist in preparing detailed strategic budgets specifically for North American clinical trials and FDA approval processes. We help align your capital raise with the high operational expenditures of foreign trials, mitigating FX risks and ensuring your R&D milestones are fully funded. This ensures that the capital you raise is deployed effectively to reach major valuation inflection points.
Our partnership extends through an 18-month strategic roadmap, moving your firm from initial public entry to full institutional readiness. We provide the long-term advisory needed to improve capital quality and liquidity, ultimately guiding your company through the strategic “uplit” to senior exchange tiers. This service is designed to maximize your firm’s valuation as you move from early-stage venture to a commercial-scale global leader.